Australia - English - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - oseltamivir phosphate, quantity: 59.1 mg (equivalent: oseltamivir, qty mg) - capsule, hard - excipient ingredients: titanium dioxide; croscarmellose sodium; povidone; sodium stearylfumarate; gelatin; pregelatinised maize starch; iron oxide black; purified talc; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; potassium hydroxide - talminex is indicated for the treatment of infections due to influenza a and b viruses in adults and children including full-term neonates. treatment should commence as soon as possible, but no later than 48 hours after the onset of the initial symptoms of infection.,talminex is indicated for the prevention of influenza in adults and children aged 1 year and older. vaccination is the preferred method of routine prophylaxis against infection with influenza virus.

Australia - English - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - oseltamivir phosphate, quantity: 39.4 mg (equivalent: oseltamivir, qty mg) - capsule, hard - excipient ingredients: gelatin; pregelatinised maize starch; titanium dioxide; iron oxide red; povidone; sodium stearylfumarate; iron oxide yellow; croscarmellose sodium; purified talc; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - talminex is indicated for the treatment of infections due to influenza a and b viruses in adults and children including full-term neonates. treatment should commence as soon as possible, but no later than 48 hours after the onset of the initial symptoms of infection.,talminex is indicated for the prevention of influenza in adults and children aged 1 year and older. vaccination is the preferred method of routine prophylaxis against infection with influenza virus.

Australia - English - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - oseltamivir phosphate, quantity: 98.5 mg (equivalent: oseltamivir, qty mg) - capsule, hard - excipient ingredients: iron oxide red; croscarmellose sodium; purified talc; iron oxide black; gelatin; titanium dioxide; pregelatinised maize starch; iron oxide yellow; sodium stearylfumarate; povidone; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; potassium hydroxide - talminex is indicated for the treatment of infections due to influenza a and b viruses in adults and children including full-term neonates. treatment should commence as soon as possible, but no later than 48 hours after the onset of the initial symptoms of infection.,talminex is indicated for the prevention of influenza in adults and children aged 1 year and older. vaccination is the preferred method of routine prophylaxis against infection with influenza virus.

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - tramadol hydrochloride - capsule, hard - 50 milligram(s) - other opioids; tramadol

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - tramadol hydrochloride, quantity: 50 mg - capsule - excipient ingredients: gelatin; indigo carmine aluminium lake; magnesium stearate; colloidal anhydrous silica; propyl hydroxybenzoate; methyl hydroxybenzoate; sodium lauryl sulfate; titanium dioxide; iron oxide yellow; sodium starch glycollate; microcrystalline cellulose - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - tramadol hydrochloride, quantity: 50 mg - capsule - excipient ingredients: maize starch; microcrystalline cellulose; lactose monohydrate; sodium starch glycollate; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; sunset yellow fcf; quinoline yellow; allura red ac; potable water; gelatin; sodium lauryl sulfate - relief of moderate to severe pain. for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ciclosporin, quantity: 100 mg - capsule, soft - excipient ingredients: propylene glycol; iron oxide black; titanium dioxide; corn glycerides; dl-alpha-tocopherol; glycerol; gelatin; ethanol; peg-40 hydrogenated castor oil; hypromellose; purified water; isopropyl alcohol; cochineal; aluminium chloride; sodium hydroxide - cyclosporin sandoz is indicated as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. for induction and/or maintenance of remission in the nephrotic syndrome. cyclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cytostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired (see precautions). for the treatment of severe, active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents (including methotrexate) are inappropriate or ineffective. in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate and the disease has caused a significant interference with the quality of life. for the treatment of severe atopic dermatitis when other treatment is ineffective or inappropriate. careful monitoring of all cyclosporin-treated patients is mandatory. cyclosporin should only be used by medical practitioners who are experienced in the use of immunosuppressive therapy (see "precautions").

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ciclosporin, quantity: 50 mg - capsule, soft - excipient ingredients: propylene glycol; ethanol; glycerol; titanium dioxide; peg-40 hydrogenated castor oil; gelatin; corn glycerides; dl-alpha-tocopherol; hypromellose; purified water; isopropyl alcohol; cochineal; aluminium chloride; sodium hydroxide - cyclosporin sandoz is indicated as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. for induction and/or maintenance of remission in the nephrotic syndrome. cyclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cytostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired (see precautions). for the treatment of severe, active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents (including methotrexate) are inappropriate or ineffective. in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate and the disease has caused a significant interference with the quality of life. for the treatment of severe atopic dermatitis when other treatment is ineffective or inappropriate. careful monitoring of all cyclosporin-treated patients is mandatory. cyclosporin should only be used by medical practitioners who are experienced in the use of immunosuppressive therapy (see "precautions").

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ciclosporin, quantity: 25 mg - capsule, soft - excipient ingredients: titanium dioxide; peg-40 hydrogenated castor oil; propylene glycol; glycerol; corn glycerides; iron oxide black; dl-alpha-tocopherol; gelatin; ethanol; hypromellose; purified water; isopropyl alcohol; cochineal; aluminium chloride; sodium hydroxide - cyclosporin sandoz is indicated as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. for induction and/or maintenance of remission in the nephrotic syndrome. cyclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cytostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired (see precautions). for the treatment of severe, active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents (including methotrexate) are inappropriate or ineffective. in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate and the disease has caused a significant interference with the quality of life. for the treatment of severe atopic dermatitis when other treatment is ineffective or inappropriate. careful monitoring of all cyclosporin-treated patients is mandatory. cyclosporin should only be used by medical practitioners who are experienced in the use of immunosuppressive therapy (see "precautions").

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - tramadol hydrochloride, quantity: 50 mg - capsule, hard - excipient ingredients: magnesium stearate; titanium dioxide; iron oxide yellow; colloidal anhydrous silica; microcrystalline cellulose; gelatin; sodium starch glycollate; sodium lauryl sulfate - zydol capsules are indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.